| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adial Pharmaceuticals, Inc$2.6
+0.06 (+2.36%)
D 21Pipeline Score Pharma · Clinical
Market Cap
5.06 M
EPS
-9.90
P/E Ratio
-0.24 $
Value Trade
49.40 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
432.53 K
Operating CF
-1.61 M
Total Assets
5.23 M
Total Liabilities
1.51 M
Equity
3.72 M
D/E Ratio
12,345
52.94 %
Week
25.3 %
1 Month
-19.69 %
3 Month
-71.31 %
6 Month
-99.87 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
4.58 M
Monthly Burn
537.00 K
Runway
7.4 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
83.99 K
52 Week Range
1.31 - 18.90
% held by Insiders
0.96 %
% held by Institutions
1.66 %
Enterprise Value
474.85 K
Total Shares
1.43 M
Short %
3.36 %
Float Shares
1.41 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D21
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 20%
Micro Cap (rank 725 of 905)
Percentile RankAdial Pharmaceuticals, Inc faces pipeline headwinds (21/100), with 1 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AD04 Small molecule | Alcohol Use Disorder | Phase 3 | NCT04101227 | 50% | - | COMPLETED | 302 | - | - | Mar 18, 2022 | - | Apr 17, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AD04 | Alcohol Use Disorder | Phase 3 | 2025-06-25 | |||
AD04 | Alcohol Use Disorder | Phase 3 | 2025-06-25 | |||
AD04 | Alcohol Use Disorder | Phase 3 | 2025-06-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADIL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Adial Pharmaceuticals, Inc (ADIL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ADIL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADIL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADIL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADIL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ADIL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADILAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals has expanded its executive leadership team by appointing Matthew Davidson as chief development officer and Julie Saiki as executive vice president of strategy. The company also announced the successful closing of a $32 million private placement, part of a larger $64 million financing effort, aimed at advancing its lead program, AT177, for ulcerative colitis.
Read more →ADILAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals has acquired Azora Therapeutics, enhancing its pipeline with Azora's lead asset, AT177, aimed at treating ulcerative colitis. The acquisition is coupled with a financing deal worth up to $64 million, which will support the advancement of AT177 through clinical milestones. The company plans to initiate Phase 1 studies in mid-2027, leveraging Azora's innovative approach to minimize systemic exposure.
Read more →ADILAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its first quarter financial results for 2026, highlighting progress in advancing its lead product, AD04, towards late-stage development. The company noted favorable regulatory discussions that could streamline the approval process and reduce costs. Additionally, a collaboration with Molteni Farmaceutici aims to establish a commercial pathway for AD04 in Europe. However, securing funding remains a critical challenge for the company's future plans.
Read more →ADILAdial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
Adial Pharmaceuticals has praised the introduction of bipartisan legislation, H.R. 7091, aimed at enhancing research and development of therapies for Alcohol Use Disorder (AUD) among veterans. This legislation acknowledges the high prevalence of AUD in the veteran population and supports non-abstinence based treatment options. Adial's AD04, a genetically targeted therapy, aligns with the updated federal definition of recovery, promoting harm reduction strategies.
Read more →ADILAdial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
Adial Pharmaceuticals has signed a collaboration framework with Molteni Farmaceutici to commercialize AD04 in Europe. The agreement outlines strategic and financial terms, with potential royalties and milestones estimated at nearly $60 million. This partnership marks a significant milestone for Adial as it aims to establish a European market presence for its treatment of Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement, following a period where its stock price exceeded $1.00 per share. This milestone supports the company's advancement of its lead drug, AD04, towards a pivotal Phase 3 clinical trial for Alcohol Use Disorder. The company is also engaged in strategic partnerships to enhance AD04's development and commercialization.
Read more →ADILAdial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Adial Pharmaceuticals has highlighted a recent FDA policy shift that may allow approval of its lead drug candidate, AD04, based on one pivotal trial instead of two. This change could significantly reduce the costs and time associated with Phase 3 trials, enhancing the company's strategic position. The FDA's new direction emphasizes trial quality over quantity, potentially benefiting Adial's development strategy.
Read more →ADILAdial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Cary Claiborne will discuss the company's progress, particularly regarding its investigational drug AD04 for Alcohol Use Disorder. The presentation will be available via webcast, and management will hold one-on-one meetings with investors during the event.
Read more →ADILAdial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals has praised a new Congressional directive that encourages the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorders, particularly Alcohol Use Disorder (AUD). This directive aims to include measures like reduced cravings and disorder severity, which align with modern treatment goals. Adial's investigational therapy, AD04, is positioned to benefit from this regulatory evolution, potentially enhancing its development path.
Read more →ADILAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Adial Pharmaceuticals announced a 1-for-25 reverse stock split effective February 5, 2026, to comply with Nasdaq's minimum bid price requirement. This action aims to enhance the attractiveness of its shares to investors while maintaining the ownership percentage of current shareholders. The company's CEO expressed optimism about future growth and the potential of their lead drug, AD04.
Read more →ADILAdial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
Adial Pharmaceuticals has announced the publication of an international patent application for its lead investigational drug, AD04, aimed at treating Alcohol Use Disorder. The patent, filed in July 2024, is expected to secure protection for the company's core assets until at least 2045. The company is planning a new Phase 3 clinical trial program to further advance AD04's development.
Read more →ADILAdial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Adial Pharmaceuticals has announced a warrant inducement agreement that will generate approximately $2.86 million in gross proceeds through the immediate exercise of existing warrants. The funds raised will be allocated for working capital and other corporate needs. This transaction is anticipated to close around December 1, 2025, pending customary conditions.
Read more →ADILAdial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals CEO Cary Claiborne appeared on The Big Biz Show, enhancing the company's visibility. The show aired on various major networks and streaming platforms. Adial's lead product, AD04, has shown promising results in its Phase 3 trial for Alcohol Use Disorder, indicating potential for broader applications in addiction treatment.
Read more →ADILAdial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals has completed the analytical validation of a cheek swab method for testing patients, marking a significant milestone for its AD04 program aimed at treating Alcohol Use Disorder. The partnership with Genomind focuses on developing a genetic test to identify suitable patients for upcoming Phase 3 trials. The FDA has confirmed that the use of this test poses Non-Significant Risk, facilitating the path towards registration and commercial application.
Read more →ADILAdial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals has received positive feedback from the FDA regarding its End of Phase 2 meeting for AD04, a treatment for Alcohol Use Disorder. The FDA's input will guide the design of the upcoming Phase 3 clinical trial. Adial aims to implement these recommendations to enhance the program's success and is optimistic about the potential market impact of AD04.
Read more →ADILAdial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days by March 2, 2026. This extension allows Adial to continue trading on the Nasdaq Capital Market under the symbol ADIL.
Read more →ADILAdial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
Adial Pharmaceuticals has received positive support from the U.S. Senate for expanding clinical trial endpoints beyond abstinence in treating Alcohol Use Disorder (AUD). This legislative support encourages the FDA to consider alternative endpoints, which aligns with Adial's strategy for its investigational drug AD04. The company believes this shift will enhance the regulatory pathway for AUD treatments and address unmet medical needs.
Read more →ADILAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its Q2 2025 financial results and highlighted significant progress in its clinical development. The company successfully completed its End of Phase 2 meeting with the FDA, receiving crucial feedback for its upcoming Phase 3 trial of AD04, a treatment for Alcohol Use Disorder. Additionally, Adial has established manufacturing agreements to ensure supply chain robustness and is optimistic about advancing its clinical program.
Read more →ADILAdial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Adial Pharmaceuticals has successfully completed its End of Phase 2 meeting with the FDA, receiving positive feedback on the Phase 3 trial design for its investigational drug AD04, aimed at treating Alcohol Use Disorder. The meeting is expected to enhance Adial's position in discussions with potential partners. The company is optimistic about the upcoming Phase 3 clinical development program.
Read more →ADILAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals has announced that it has regained compliance with Nasdaq's stockholders' equity listing requirement, maintaining a minimum of $2.5 million in equity. CEO Cary Claiborne expressed satisfaction with this achievement, emphasizing its importance for investor confidence and the company's growth strategy. Adial is focused on developing treatments for addiction, with its lead product AD04 showing promise in clinical trials.
Read more →ADILAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
Adial Pharmaceuticals has filed a PCT patent application to protect its core assets, specifically for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder. This application is expected to extend intellectual property exclusivity until at least 2045. The company is preparing for an EOP2 Meeting with the FDA scheduled for July 29, 2025.
Read more →ADILAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Adial Pharmaceuticals has entered into agreements with Cambrex and Thermo Fisher Scientific for the manufacturing of its lead drug candidate, AD04, aimed at treating Alcohol Use Disorder. These partnerships will support upcoming clinical trials and the New Drug Application submission to the FDA. The collaboration is expected to streamline production and ensure compliance with regulatory requirements.
Read more →Competitive Position
How ADIL ranks across every disease it competes inCompetitive Position is a premium feature
See how ADIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial